The impact of chip technology on cancer medicine by Fey, M. F.
DOI: 10.1093/annonc/mdf647
© 2002 European Society for Medical Oncology
The impact of chip technology on cancer medicine
M. F. Fey
Institute of Medical Oncology, Inselspital, Bern, Switzerland
Introduction
Cancers are caused through gene mutations and other types of
chromosomal or molecular abnormalities. The rare hereditary
cancer predisposition syndromes have been given much atten-
tion in recent years, because genes were found that account for
the marked preponderance of particular neoplasms in such
families. Individuals with hereditary cancer predisposition
display germline mutations in such genes in their constitu-
tional DNA [1]. The frequent sporadic cancers, i.e. cancers in
individuals with a negative family history for cancer, carry
somatic gene mutations acquired at mitosis. Genes implicated
in cancers are mostly those involved in normal homeostasis of
cellular proliferation, differentiation and death [2]. Cancer
development usually requires that several different gene
mutations accumulate in a cell of origin, and in its subclones
during clonal evolution of malignant growth [3, 4]. Gene
mutations in cancers invariably lead to alterations of gene
expression patterns with respect to normal cellular counter-
parts, including the mutated genes themselves and their down-
stream targets. An overview of genes and their expression
profiles possibly involved in cancer is essential to gain a
detailed understanding of molecular carcinogenesis. Molec-
ular data may be of clinical use to improve cancer diagnosis,
to assess prognosis or (perhaps more importantly) to predict
appropriate treatment selection. Until now most research
efforts in this field have been directed at characterising single
genes, which in one way or another contribute to the develop-
ment of particular cancers. The human DNA sequence data
bank, created by the Human Genome Project [5, 6], and
associated technologies now provide new means to broaden
this approach and to obtain more global views on cancer
genes.
In molecular studies on cancer a single candidate gene is
often chosen for further detailed analysis. The selection of
such genes implies some sort of ‘educated guessing’. For
example, a gene might be attractive because it is known to be
involved in cellular differentiation, or because it is located in a
genomic area which is targeted by chromosomal aberrations
in a particular tumour type. This approach towards finding
‘new’ roles for genes in cancer is deliberately biased, whilst a
random screening of gene expression in tumours would
perhaps open up new avenues of research.
The molecular diagnostics of cancers
Clinical use of molecular data on human cancers requires that
in diagnostic material molecular markers can be detected in an
easy and reproducible way. Increasingly, genes and gene
products are being investigated for their diagnostic use, and
they may complement time-honoured techniques such as
chemical cell and tissue staining. Immunostaining of tissue
sections with specific antibodies or sensitive polymerase-
chain reaction (PCR or RT-PCR) techniques are applicable
not only to fresh but also to archival tissue [7]. Examples are
the immunohistochemical detection of estrogen receptors in
breast cancer, or the CD20 antigen in B-cell lymphoma.
Molecular diagnostics may nowadays explore an astonish-
ingly wide variety of nucleic acid sources for tumour diagno-
sis. DNA or RNA extracted from bone marrow can be used to
detect specific chromosomal translocations in leukaemia by
PCR [8]. Sensitive molecular techniques allow us to detect
tumour cells in urine [9], in stool for colorectal cancer screen-
ing [10] and in bronchial lavage material [11], provided that
suitable and specific genetic tumour markers are available.
Since the Human Genome Project now maps thousands of
genes and their sequences [5, 6], a wealth of genetic informa-
tion has become available for potential diagnostic use. How-
ever, many molecular methods may be too cumbersome to
survey all relevant molecular markers in a tumour biopsy.
New techniques may help to overcome this limitation. The
tissue microarray technology (not to be mistaken for the DNA
microarrays to be discussed later) permits high-throughput
molecular profiling of tumour specimens without tissue
culture [12, 13]. As many as 1000 individual small tumour
tissue samples are taken from blocks of tumours and com-
posed into a new ‘recipient’ block. Sections of this recipient
block allow the parallel detection of multiple molecular DNA
markers [for example, with fluorescent in situ hybridisation
(FISH)], the measurement of mRNA expression or the tracing
of protein targets by immunohistochemistry. Tissue micro-
arrays are well suited to absorb the diagnostic work-load
potentially created by the impending inflow of generous
molecular information from the human genome databank.
Molecular methods exploiting extracted nucleic acids often
require that the diagnostic material contains enriched tumour
cells, with as little ‘contamination’ with non-neoplastic cells
as possible. This is particularly important for studies speci-
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fically looking at gene expression in tumour cells. Leukaemic
cells may be enriched through density-gradient centrifugation
of peripheral blood samples. In solid tumours, laser-directed
microdissection now permits the preparation of enriched
tumour samples suitable for molecular studies, and even
single cancer cells may be studied [14–16].
Analyses of cancers with DNA microarrays
Most established molecular diagnostic techniques are inade-
quate to permit the comprehensive screening of a tumour
biopsy sample for all possible types of genetic markers.
Hitherto, standard molecular diagnostics such as the Southern
blot have depended on tagged specific DNA probes comple-
mentary to the sequences of interest in a sample. PCR is based
on the specific annealing of nucleic acid sequences (known as
primers), to the left and to the right of a gene sequence of inter-
est, which thus enable specific amplification of a defined
stretch of DNA or RNA. Technological advances have now
permitted these standard molecular detection methods to be
miniaturised. DNA microarrays are also known as ‘chips’,
biochips, or gene arrays, not to be confused with the tissue
arrays discussed above. DNA microarrays typically consist of
rows and rows of oligonucleotide sequence strands, or cDNA
sequences immobilised and lined up in dots on a silicon chip
or glass slide (Figure 1). Arrays can accommodate up to
20 000 specific sequences on a single chip, either chosen
randomly, or deliberately ‘biased’ to represent collections of
genes typically expressed in a cell type of interest, for
example, lymphoid B-cells. With further advances of the
technology, it is likely that single chips will contain compre-
hensive human cDNA or oligo sequence banks [17–19].
The major application of microchips falls into three
categories (Table 1):
1. Gene expression profiling. RNA is extracted from tumour
samples and hybridised to the microarray to assess simul-
taneously and in a single experiment the expression of
thousands of genes within the sample.
2. Genotyping. Genomic DNA from an individual is tested for
hundreds or thousands of genetic markers [notably single
nucleotide polymorphisms (SNPs) or ‘snips’, or microsatel-
lite markers] in a single hybridisation. This will yield a
genetic fingerprint which in turn may be linked to the risk of
developing single gene disorders or particular common
complex diseases.
3. DNA sequencing. Sequence variations of specific genes can
be screened in a test DNA sample, thereby greatly increas-
ing the scope for precise molecular diagnosis in single gene
disorders or complex genetic diseases.
In cancers, the diagnostic material usually consists of RNA
samples extracted from tumours of interest which are labelled
Figure 1. The principle of cDNA microarray gene expression analysis in tumours. Schematic representation of a DNA microchip. The chip (left panel) 
consists of a siliconised or glass surface (an area of about 1 cm2) where up to 10 cDNAs or 250 oligonucleotide gene sequences are plotted in an orderly 
fashion. In the two-colour hybridisation scheme usually employed, labelled RNA from tumour samples 1–4 is hybridised to the chip simultaneously and 
in direct competition with labelled RNA from defined control samples. Different fluorescent dyes are used for sample and control RNA (shown here in 
black and white). The relative difference in gene expression between tumour and normal cells can be quantified through image analysis of the chip, and 
assessed as relative amounts of the two different fluorochrome signals arising from each defined quadrant of the chip (scale shown below the main 
panel). Tumours 1 and 2 show identical expression patterns of genes A and B, and may thus be grouped together by virtue of a clustered gene expression 
profile. In contrast, tumours 3–5 carry distinct molecular signatures with respect to the expression of these two genes.
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for hybridisation on chips to study large-scale gene expression
profiles. The use of RNA implies that freshly frozen intact
tumour tissue must be used, but methods permitting the study
of fixed tissue (where RNA is usually much degraded) are
under active investigation. Many protocols foresee a com-
parative and competitive hybridisation of tumour RNA
samples on the chip against normal or reference RNA labelled
with different colours (Figure 1). As with more traditional
molecular diagnostic methods, the enrichment of tumour cells
is important. This can be achieved by ‘virtual dissection’ of
chip data in a computer where gene groups may be clustered
and filtered out which are known to be derived from normal
cells or from inflammatory infiltrates in a tumour. Laser-
capture microdissection to isolate tumour cells mechanically
may, however, still be necessary, although more laborious
[20].
The ‘Lymphochip’ is a cDNA microarray collecting genes
preferentially expressed in lymphoid cells [21]. Lymphoid
malignancies studied with this chip exhibit an orderly picture
of gene expression patterns, reflecting both B- or T-cell
lineage characteristics, stage of maturation of lymphoid cells
and proliferation signatures. Diffuse large B-cell lymphoma
(a clinically heterogeneous group of lymphomas despite
morphological similarity) can be split into subtypes exhibiting
gene expression profiles either typical of germinal centre
B-cells, or activated B-cells, perhaps with implications for
prognosis.
On histology, one invasive-ductal breast cancer specimen
may look deceptively similar to another one. Clinically the
cases may be totally different, due to inherent biological dif-
ferences elusive to morphological analysis. Gene expression
patterns in human breast cancer specimens display distinct
molecular portraits [22, 23]. Tumours may be clustered into
subgroups by gene expression patterns, possibly representing
distinct subtypes or entities of breast cancer.
In acute lymphoblastic and myeloid leukaemias [acute
lymphoblastic leukaemia (ALL) and acute myelogenous
leukaemia (AML), respectively] microchip analysis can
define groups of genes, which neatly distinguish AML from
ALL; their expression being high in one type of leukaemia and
low in the other [24]. Interestingly, genes most useful for
AML versus ALL class prediction are not necessarily markers
of haematopoietic lineage. Non-lineage restricted genes
encoding cell cycle proteins, cell adhesion molecules and the
like may also help to sort out AML from ALL.
Astrocytomas are heterogeneous glial neoplasms ranging
from indolent astrocytomas to highly aggressive malignant
glioblastoma multiforme. Microarrays may identify molecu-
lar signatures distinguishing between these two tumour types
which may be relevant for diagnosis and therapy [25].
Classification of human tumours according to their original
anatomical site, i.e. their primary tumour, is important in the
management of patients. Chips may identify subsets of genes
whose expression is characteristic for each cancer class, e.g.
breast cancer versus colorectal cancer versus bladder cancer,
etc. [26]. Predictor genes include genes typically expressed in
specific epithelial differentiation processes of the correspond-
ing normal tissues. Thus microchips can be used to predict the
tissue of origin of a carcinoma in the context of multiple
cancer classes. This might be particularly helpful for further
classification of metastatic cancer with unknown primary site.
A very important potential of the chip technology will be the
definition of new molecular factors predicting treatment suc-
cess or failure. Targeting of therapy may improve treatment
results, cut down on side effects and reduce costs potentially
spent on a priori useless drugs. In breast cancer expression of
estrogen receptors predicts response to hormone treatment. A
high score of HER2/c-erbB2 expression is mandatory for the
therapeutic success of monoclonal antibodies against this
oncoprotein [27, 28]. CML hit the headlines when a new drug,
STI571 or GlivecR, interfering specifically with the BCR-ABL
tyrosine kinase activity in this leukaemia was shown to be
clinically active [29]. DNA microchips may identify genes or
gene expression clusters in tumours, which may predict sens-
itivity or resistance to particular drugs [30]. For example,
cDNA microarray analyses of oesophageal tumours were able
to predict the outcome of adjuvant chemotherapy, since par-
ticular gene expression clusters (rather than expression of
single genes) were correlated with sensitivity or resistance to
cisplatin or 5-fluorouracil [31]. In brief, specific genetic
Table 1. Applications of DNA microarrays or ‘chips’ in oncology
• Global understanding of abnormal gene expression contributing to malignancy, i.e. snapshots of genes either
up- or down-regulated in tumours
• Molecular classification of neoplasms by gene expression signatures, predicting the tissue of origin of a
tumour in the context of multiple cancer classes
• Identification of novel molecular-based subclasses of tumours with clinical relevance
• Discovery of new prognostic or predictive indicators and biomarkers of therapeutic response
• Identification and validation of new molecular targets for drug development
• Prediction of drug side effects during preclinical development and toxicology studies
• Identification of genes conferring drug resistance
• Prediction or selection of patients most likely to benefit from, or suffer from particular side effects of drugs
(pharmacogenomics)
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aberrations or gene expression profiles may become important
in determining the appropriate choice of cancer treatment. The
human genome sequence databank hosts all of these genes,
many of which still await their discovery, characterisation and
their being put to clinical use.
Problems and outlook
Molecular diagnostics with DNA microarrays do not displace
time-honoured diagnostic tools such as morphology. The
demands on bio-informatics to handle the impressive data
flow generated by microchips are considerable, and costs still
excessive. The DNA chip of microarray technology shares the
problem of standardisation with other molecular diagnostic
techniques. Considerable efforts still need to be invested in
order to build up a system similar to the quality control
networks established, for example, to monitor the quality of
coagulation laboratory tests. The clinical relevance of the chip
data in cancer specimens will have to be tested in appropriate
clinical trials. To sort out clustered gene expression patterns,
to define subgroups or ‘new’ entities of common cancers, to
test ‘new’ cancer genes for their prognostic or predictive
value, or to study the therapeutic value of new custom-
designed drugs provides a formidable task, which will require
new strategies from the clinical side.
The screening of tumour gene expression profiles with
DNA microchips is a powerful strategy to discover new candid-
ate genes with distinct roles in molecular cancer pathology. It
possibly avoids the type of cumbersome mapping and cloning
experiments hitherto required to define ‘new’ genes. How-
ever, the fact that a gene cluster is over-expressed, or silent in
a cancer cell, raises hypotheses on the role of the genes in
carcinogenesis, but gives no final clues. Global gene expres-
sion profiling of cancers with the DNA chip technology is now
a reality, but the detailed characterisation of single genes
elucidating their possible role in carcinogenesis is far from
being outdated. Whilst DNA represents genomic hardware,
and RNA a sort of genetic ‘interim’ software, the final pro-
duct, protein, ultimately matters in the life of a cell. In the
aftermath of the Human Genome Project, new strategies to
characterise and detect human proteins in biological material
(including clinical specimens) are now mandatory and indeed
on the horizon. The new technology of proteomics is on track
to provide a new wave of fascinating data with a great poten-
tial for cancer medicine [32, 33].
Acknowledgements
The author’s experimental research is generously supported
by the Swiss National Foundation, the Swiss and the Bernese
Cancer League, the Marlies-Schwegler Foundation, the Hecht-
Foundation and the Bernese Foundation for Clinical Cancer
Research.
References
1. Lindor NM, Greene MH and the Mayo Familial Cancer Program. The
concise handbook of family cancer syndromes. J Natl Cancer Inst
1998; 90: 1039–1071.
2. Fey MF. Molecular biology of cancer. In Cavalli F, Hansen HH,
Kaye SB (eds): Textbook of Medical Oncology, 2nd edition. London:
Martin Dunitz 2000; 1–66.
3. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations
during colorectal-tumor development. N Engl J Med 1988; 319:
525–532.
4. Wainscoat JS, Fey MF. Assessment of clonality in human tumors: a
review. Cancer Res 1990; 50: 1355–1360.
5. International Human Genome Sequencing Consortium. Initial
sequencing and analysis of the human genome. Nature 2001; 409:
860–921.
6. Venter JC, Adams MD, Myers EW et al. The sequence of the human
genome. Science 2001; 291: 1304–1352.
7. Sidransky D. Nucleic acid-based methods for the detection of cancer.
Science 1997; 278: 1054–1059.
8. Fey MF, Pilkington SP, Summers C, Wainscoat JS. Molecular
diagnosis of haematological disorders using DNA from stored bone
marrow slides. Br J Haematol 1987; 67: 489–492.
9. Steiner G, Schoenberg MP, Linn JF et al. Detection of bladder cancer
recurrence by microsatellite analysis of urine. Nature Med 1997; 3:
621–624.
10. Dong SM, Traverso G, Johnson C et al. Detecting colorectal cancer in
stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;
93: 858–865.
11. Liloglou T, Maloney P, Xinarianos G et al. Cancer-specific genomic
instability in bronchial lavage: a molecular tool for lung cancer
detection. Cancer Res 2001; 61: 1624–1628.
12. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for
high-throughput molecular profiling of tumor specimens. Nature
Med 1998; 4: 844–847.
13. Bubendorf L, Kononen J, Koivisto P et al. Survey of gene ampli-
fications during prostate cancer progression by high-throughput
fluorescence in situ hybridisation on tissue microarrays. Cancer Res
1999; 59: 803–806.
14. Emmert-Buck MR, Bonner RF, Smith PD et al. Laser capture micro-
dissection. Science 1996; 274: 998–1001.
15. Rubin MA. Use of laser capture microdissection, cDNA microarrays,
and tissue microarrays in advancing our understanding of prostate
cancer. J Pathol 2001; 195: 80–86.
16. Hasse U, Tinguely M, Oppliger Leibundgut E et al. Clonal loss of
heterozygosity in Hodgkin/Reed–Sternberg cells. J Natl Cancer Inst
1999; 91: 1581–1583.
17. Liotta L, Petrocoin E. Molecular profiling of human cancer. Nature
Rev 2000; 1: 48–56.
18. Ramsay G. DNA chips: state-of-the-art. Nature Biotech 1998; 16:
40–44.
19. Aitman TJ. DNA microarrays in medical practice. Br Med J 2001;
323: 611–615.
20. Alizadeh AA, Ross DT, Perou CM, van de Rijn M. Towards a novel
classification of human malignancies based on gene expression
patterns. J Pathol 2001; 195: 41–52.
21. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse
large B-cell lymphoma identified by gene expression profiling.
Nature 2000; 403: 503–511.
113
22. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human
breast tumours. Nature 2000; 406: 747–752.
23. West M, Blanchette C, Dresman H et al. Predicting the clinical status
of human breast cancer by using gene expression profiles. Proc Natl
Acad Sci USA 2001; 98: 11462–11467.
24. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of
cancer: class discovery and class prediction by gene expression
monitoring. Science 1999; 286: 531–537.
25. Rickman DS, Bobek MP, Misek DE et al. Distinctive molecular pro-
files of high-grade and low-grade gliomas based on oligonucleotide
microarray analysis. Cancer Res 2001; 61: 6885–6891.
26. Su AI, Welsh JB, Sapinoso LM et al. Molecular classification of
human carcinomas by use of gene expression signatures. Cancer Res
2001; 61: 7388–7393.
27. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus
a monoclonal antibody against HER2 for metastatic breast cancer that
overexpresses HER2. N Engl J Med 2001; 344: 783–792.
28. Thor AD, Berry DA, Budman DR et al. erbB2, p53, and efficacy of
adjuvant therapy in lymph node positive breast cancer. J Natl Cancer
Inst 1998; 90: 1346–1360.
29. Druker BJ, Talpaz M, Resta D et al. Efficacy and safety of a specific
inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid
leukemia. N Engl J Med 2001; 344: 1031–1037.
30. Scherf U, Ross DT, Waltham M et al. A gene expression database
for the molecular pharmacology of cancer. Nature Genet 2000; 24:
236–244.
31. Kihara C, Tsunoda T, Tanaka T et al. Prediction of sensitivity of
esophageal tumours to adjuvant chemotherapy by cDNA microarray
analysis of gene-expression profiles. Cancer Res 2001; 61: 6474–
6479.
32. Dua K, Williams TM, Beretta L. Translational control of the
proteome: relevance to cancer. Proteomics 2001; 1: 1191–1199.
33. Martin DB, Nelson PS. From genomics to proteomics: techniques
and applications in cancer research. Trends Cell Biol 2001; 11:
S60–S65.

